Publicacions en col·laboració amb investigadors/es de University Medical Center Utrecht (3)

2021

  1. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 643-654

  2. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

    European Journal of Cancer, Vol. 158, pp. 156-168

2008

  1. Subcutaneous panniculitis-like T-cell lymphoma: Definition, classification, and prognostic factors: An EORTC Cutaneous Lymphoma Group Study of 83 cases

    Blood, Vol. 111, Núm. 2, pp. 838-845